Results 171 to 180 of about 22,494 (197)
Some of the next articles are maybe not open access.
2015
Great strides had been made in the war against cancer with chemotherapy even before the emergence of protein kinase inhibitors. For instance, prior to vinblastine (1, Velban) became available in 1964 for the treatment of lymphoma, the diagnosis of Hodgkin’s disease (a cancer of the lymph nodes) was virtually a death sentence.
openaire +1 more source
Great strides had been made in the war against cancer with chemotherapy even before the emergence of protein kinase inhibitors. For instance, prior to vinblastine (1, Velban) became available in 1964 for the treatment of lymphoma, the diagnosis of Hodgkin’s disease (a cancer of the lymph nodes) was virtually a death sentence.
openaire +1 more source
Imatinib Mesylate Induced Erythroderma.
The Journal of the Association of Physicians of India, 2019Imatinib, a specific tyrosine kinase inhibitor is a new anticancer agent, which has shown excellent efficacy in managing chronic myeloid leukemia. It is well tolerated with few side effects. Commonest adverse events are maculopapular eruptions and periorbital edema were reported. Severe adverse reactions are seen in 5% of patients.
Snehal, Lunge, Rohan, Bhise
openaire +1 more source
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
New England Journal of Medicine, 2002George D Demetri +2 more
exaly
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
New England Journal of Medicine, 2002Hagop M Kantarjian +2 more
exaly
Imatinib Mesylate, Increased Bone Formation, and Secondary Hyperparathyroidism
New England Journal of Medicine, 2006Andrew Grey, Susannah O'Sullivan
exaly
Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate
New England Journal of Medicine, 2006Robert G Maki
exaly